Search | Clinical Trials Finder

Conditions: Melanoma (Skin)
Interventions: MART-1, NY-ESO-1, gp100:209-217(210M), gp100:280-288(288V), Montanide ISA 51 VG, BMS-936558; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
Interventions: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis, sargramostim; Biological · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions: decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay; Drug · Biological · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Melanoma
Interventions: CP 870,893, Peptides, Oncovir poly IC:LC; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Myelogenous Leukemia
Interventions: Vaccine; Biological
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Melanoma (Skin)
Interventions: Autologous dendritic cell-adenovirus CCL21 vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Myeloma
Interventions: MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Prostate Cancer
Interventions: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis; Drug · Biological · Radiation + 2 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: NY-ESO-1 peptide vaccine; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: NY-ESO-1-expressing Tumors
Interventions: Vaccine only, Vaccine + cyclophosphamide; Biological
Lead sponsor: Hassane M. Zarour, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Transitional Cell Carcinoma
Interventions: TICE®-strain BCG, NY-ESO-1 protein, sargramostim; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Neoplasm
Interventions: aldesleukin, fludarabine phosphate, cyclophosphamide, laboratory biomarker analysis, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, fludeoxyglucose F 18, positron emission tomography; Biological · Drug · Other + 2 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 peptide vaccine, aldesleukin, filgrastim, incomplete Freund's adjuvant, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
Interventions: WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Unresectable or Metastatic Melanoma
Interventions: Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide, NY-ESO-1 OLP4 Vaccine with Poly-ICLC; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia

Conditions: Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Nivolumab, NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL, NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine, Positron Emission Tomography; Biological · Drug · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 peptide vaccine, aldesleukin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: NY-ESO-1 OLP4, NY-ESO-1 OLP4 + Montanide, NY-ESO-1 OLP4 + Montanide + Poly-ICLC; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma
Interventions: DC Vaccine, Montanide Vaccine, Poly-ICLC; Biological
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma
Interventions: NY-ESO-1 peptide vaccine, sargramostim; Biological
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3
Interventions: NY-ESO-1 Peptide vaccine, Toripalimab-tpzi; Biological · Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Search by objective public record fields.

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients